Fractyl Health (GUTS) Q3 2026 Earnings Call Transcript
Fractyl Health (GUTS) reported Q3 2026 earnings, highlighting positive results from the REMAIN-1 study of its Revita procedure. The study met its 6-month co-primary endpoint with high statistical significance, showing patients maintained 80% of weight loss after stopping tirzepatide. The company plans to submit a de novo marketing application this quarter and expects 12-month data in Q1 2027.
How this was made

The 30-second read
Why it matters
The trial met its 6‑month co‑primary endpoint with statistically significant weight‑loss retention, suggesting a viable alternative to GLP‑1 drugs.
Market read
First disclosure of positive trial data could drive short‑term price appreciation and spark interest in the obesity‑treatment market.
What to watch
Potential regulatory hurdles and payer coverage decisions could delay commercialization.
Background
Fractyl Health presented its Q3 2026 earnings call, highlighting results from the REMAIN-1 trial of its Revita duodenal ablation procedure.
Market effects
Positive trial data may boost the bariatric device sector and related biotech stocks.
Primarily U.S. biotech and medical device markets.
Limited to investors tracking obesity‑treatment innovations worldwide.
Counterpoint
Skeptics may question long‑term durability of weight‑loss benefits and reimbursement risk.
Key entities
- companyFractyl Health
Developer of the Revita obesity‑treatment device.
- clinical_trialREMAIN-1
Phase trial evaluating Revita versus sham procedure.